Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

17.88 +0.38 (+2.14%)
Streaming Delayed Price Updated: 1:32 PM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
News headline image
3 Reasons AMRX is Risky and 1 Stock to Buy Instead
Amneal currently trades at $16.70 and has been a dream stock for shareholders. It’s returned 283% since July 2021, blowing past the S&P 500’s 72.3% gain. The... 
Via StockStory
Topics Stocks
News headline image
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AM... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Mooning Stock Worth Your Attention and 2 We Question
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a... 
Via StockStory
News headline image
1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Q4 2025 Earnings Beat on Strong Profitability ↗
Via Chartmill
Topics Earnings
News headline image
3 Russell 2000 Stocks with Open Questions
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase ↗
Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics... 
Via MarketBeat
News headline image
Why Amneal (AMRX) Stock Is Trading Up Today
What Happened? Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 5.7% in the afternoon session after the U.S. Food and Drug Admini... 
Via StockStory
News headline image
3 Profitable Stocks with Open Questions
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
Topics Economy
News headline image
Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
2 Reasons AMRX is Risky and 1 Stock to Buy Instead
Amneal trades at $12.64 and has moved in lockstep with the market. Its shares have returned 6.2% over the last six months while the S&P 500 has gained 7.9%. ... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Amneal (AMRX) Q3 2025 Earnings Call Transcript ↗
Amneal (AMRX) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Amneal (AMRX) Q2 2025 Earnings Transcript ↗
Amneal (AMRX) Q2 2025 Earnings Transcript 
Via The Motley Fool
Topics Supply Chain
News headline image
1 Value Stock to Target This Week and 2 Facing Challenges
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
News headline image
Amneal (AMRX) Q1 2026 Earnings Transcript ↗
Amneal (AMRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Amneal (AMRX) Q1 Earnings Report Preview: What To Look For
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Friday before market hours. Here’s what you need to know. Amneal ... 
Via StockStory
News headline image
Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy ... 
Via StockStory
Topics Economy
News headline image
2 Cash-Producing Stocks to Research Further and 1 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks We Steer Clear Of
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
3 Small-Cap Stocks Walking a Fine Line
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Amneal’s 34% return over the past six months has outpaced the S&P 500 by 30.9%, and its stock price has climbed to $13.16 per share. This performance may hav... 
Via StockStory
Topics Stocks
News headline image
3 Value Stocks We’re Skeptical Of
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
Why Amneal (AMRX) Stock Is Trading Lower Today
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell 6.3% in the afternoon session after the company reported fourth-quarter results that beat expectations but provided a... 
Via StockStory
News headline image
Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗
Amneal (AMRX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 11.5% year on year to $814.3 million. On the other hand,... 
Via StockStory
News headline image
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Friday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Supreme Court Strikes Down IEEPA Tariffs, Mandating Billions in Immediate Rebates
In a seismic shift for global trade and constitutional law, the Supreme Court of the United States ruled on February 20, 2026, that the executive branch lacks the authority to unilaterally impose... 
Via MarketMinute
Topics Bonds Economy Government
News headline image
3 Russell 2000 Stocks We Find Risky
Via StockStory
News headline image
3 Small-Cap Stocks That Fall Short
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.